Replimune shares plummet as skin cancer therapy fails mid-stage study

Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly re

Related Keywords

Massachusetts ,United States ,Evan Seigerman ,Replimune Group ,Skin Cancer ,Parp1 ,Replimune ,Libtayo ,Vcrr ,Complete Response Rate ,Bmo Capital ,